Mitochondrial control of apoptosis: the role of cytochrome c  by Cai, Jiyang et al.
Mitochondrial control of apoptosis: the role of cytochrome c
Jiyang Cai, Jie Yang, Dean P. Jones *
Department of Biochemistry, Emory University, Atlanta, GA 30322 USA
Received 29 January 1998; accepted 18 February 1998
Abstract
Mitochondrial cytochrome c (cyt c) has been found to have dual functions in controlling both cellular energetic
metabolism and apoptosis. Through interaction with apoptotic protease activating factors (Apaf), cyt c can initiate the
activation cascade of caspases once it is released into the cytosol. The loss of a component of the mitochondrial electron
transport chain also triggers the generation of superoxide. Although cyt c can be released independent of the mitochondrial
permeability transition (MPT), the accompanying cellular redox change can trigger the MPT. Since another apoptotic
protease, AIF, is released by MPT, the two separate pathways provide redundancy that ensures effective execution of the cell
death program. Anti-apoptotic Bcl-2 family proteins function as gatekeepers to prevent the release of both cyt c and AIF. In
spite of their stabilization effect on the mitochondrial outer membrane, Bcl-2 proteins may also be involved in the direct
binding of Apaf molecules as regulatory elements further downstream from the mitochondrial apoptotic signals. ß 1998
Elsevier Science B.V. All rights reserved.
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1. Introduction
In the last 2 years, at least two mitochondrial pro-
teins, cytochrome c (cyt c ) [1] and apoptosis induc-
ing factor (AIF) [2], have been identi¢ed as key sig-
naling molecules of apoptosis [3]. These ¢ndings have
dramatically a¡ected the understanding of the in-
volvement of mitochondria in controlling of cell
death. This review will summarize some of these re-
cent ¢ndings, particularly relevant to cyt c, and dis-
cuss possible models for the involvement of mito-
chondria during apoptosis.
Mitochondria are well known to have a central
role in energy metabolism [4], ion homeostasis [5]
and redox regulation [6], and damage to the mito-
chondria has long been linked to cell death [7]. Mi-
tochondrial respiratory inhibitors and agents that in-
duce mitochondrial swelling or loss of the membrane
potential can result in cellular energetic failure, Ca2
overloading, generation of reactive oxygen species
(ROS), loss of osmotic regulation and cell death.
Among numerous examples are KCN toxicity and
ischemia, which typically produce a necrotic mor-
phology in which cells swell and lyse, with loss of
cytoplasmic contents and appearance of distorted
and swollen organelles [8]. Mapping of the mitochon-
drial genome [9] has also provided the foundation for
understanding the role of mitochondria in aging and
genetic diseases [10]. However, until recently, the role
of mitochondria in cell death was typically consid-
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ered to be passive, re£ecting damage to critical mi-
tochondrial functions that would result in cell death.
When Kerr et al. [11] proposed apoptosis as a
unique type of cell death that is distinct from ne-
crosis, they pointed out that the ultrastructure of
cytosolic organelles, including mitochondria, was
well preserved while the nuclear chromatin had ag-
gregated and cytoplasmic contents had condensed as
an overall shrinkage of the cell took place [11^13].
Electron microscopy showed that even in phagocy-
tosed apoptotic bodies, mitochondria had nearly nor-
mal appearance [11,12]. These morphological ¢nd-
ings have been further con¢rmed by later studies
[14,15] and the preservation of mitochondrial struc-
ture and function has been viewed as a hallmark of
apoptosis, as in contrast to necrosis where mitochon-
dria are swollen and disrupted. Indeed, a normal
supply of ATP, as provided by intact mitochondria,
would appear as a requisite for ‘controlled’ cell dele-
tion [16^18]. In support of this, morphologically in-
tact mitochondria were found to be a required com-
ponent for the nuclear apoptosis in a cell-free system
using Xenopus egg extracts [19].
However, the early recognition that Bcl-2, a mam-
malian homologue of the anti-death protein Ced-9 of
Caenorhabditis elegans, is largely localized on the
outer membrane of mitochondria [20^23] forced con-
sideration that the mitochondria may have a role
other than simply energy production. An attractive
hypothesis was proposed that ROS generated from
the mitochondrial electron transport chain could
provide an apoptotic signal and Bcl-2 could function
as an antioxidant [23,24]. Indeed, over-expression of
Bcl-2 was found to inhibit both the nuclear apoptosis
and mitochondrial generation of ROS [23,24]. But
since cells lacking mtDNA (b0 cells), and cells cul-
tured under anaerobic conditions where the genera-
tion of ROS was limited, still could be induced to
undergo apoptosis [25^27], this oxidant signaling hy-
pothesis did not provide a totally satisfactory explan-
ation for the role of mitochondria in apoptosis.
2. Mitochondrial cytochrome c release and signaling
of apoptosis
Considerable clari¢cation for the role of mitochon-
dria in apoptosis was obtained when Liu et al. [1]
found that cyt c is an essential component of the
complex that activates the death protease caspase-3
(CPP32). During puri¢cation of the components for
the in vitro reconstitution of caspase-3 activation,
they found that an active fraction was ‘noticeably
pink’ [1] and had the typical cyt c absorbance
spectrum. They showed by microsequencing that
this was cyt c. In non-apoptotic HeLa cell cytosolic
extracts, cyt c, together with either dATP (WM) or
ATP (mM), could activate caspase-3 and subsequent
nuclear DNA fragmentation. Immunodepletion of
cyt c abolished this activation, and addition of puri-
¢ed cyt c restored the activation. This research pro-
vided the ¢rst direct evidence for the involvement of
a mitochondrial protein in the activation of apopto-
sis.
Cytochrome c is a 12.3 kDa, nuclear DNA en-
coded protein. Its precursor, apocytochrome c, is
synthesized on free ribosomes in the cytoplasm and
can spontaneously insert into the mitochondrial out-
er membrane via a non-receptor mediated process
[28,29]. With its further interaction with mitochon-
drial cytochrome c heme lyase, heme is incorporated,
and the protein refolds and is released into the mi-
tochondrial intermembrane space. The functional cyt
c then binds with cytochrome oxidase via its surface
positive charges. Both the X-ray crystallographic and
solution structures of cyt c have been resolved [30^
33]. As part of the mitochondrial electron transport
chain, cyt c has a very well de¢ned and speci¢c func-
tion in transfer of electrons between complex III
(ubiquinol: cytochrome c oxidoreductase) and com-
plex IV (cytochrome oxidase). Thus, the observation
that it is a component of the activation system for
caspase-3 established a second and apparently inde-
pendent function of this hemoprotein. Of interest,
this latter function does not seem to depend upon
the redox activity of the cytochrome [34,35].
Numerous studies with intact cells and in vitro cell
free systems have already provided strong support
for the ¢ndings of Liu et al. [1]. In HL60, CEM,
HeLa, Jurkat, U937, FL5.12 and cultured cerebellar
granule neuronal cells [36^41], a variety of apoptotic
stimuli, including treatment with staurosporine, eto-
poside, paclitaxel, UVB, ionizing irradiation, anti-
Fas, growth factor withdraw, peroxides and MPP,
all could induce the release of cyt c before the casp-
ase-3 activation and nuclear apoptosis (Table 1).
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With in vitro systems, cyt c was found to activate
caspase in cytosolic extracts isolated from Xenopus
eggs and Jurkat, HeLa, HL60, CSM 14.1 and NSC
cells [34^41]. Where studied, mitochondria were
found to maintain the membrane potential while
cyt c was released and caspases were activated
[36,37,41].
Studies of cyt c from di¡erent species indicate that
the role of cyt c in apoptosis is widespread and com-
mon. Cyt c is a highly conserved protein and cyt c
from horse, bovine, rat, pigeon and tuna [1,34] all
could reconstitute the caspase activation in vitro.
Yeast cyt c, partially acetylated cyt c or biotinylated
cyt c were inactive, as were apocytochrome c, heme
alone, microperoxidase-11, cytochrome b5, cyto-
chrome P-450 (2E1) or heat inactivated cyt c
[34,35]. In contrast, the redox state of cyt c was
not related to the caspase-3 activation, as illustrated
by the fact that copper or zinc substituted non-oxi-
dizable cyt c were still active. Although potassium
ferricyanide could inhibit the caspase-3 activation,
this e¡ect was thought to be further downstream
from cyt c [34,35]. Thus, cyt c appears to function
as a molecular adaptor rather than as a redox active
component during the activation of caspase-3.
Although most studies indicate that cyt c loss from
mitochondria is due to its release into the cytoplasm,
Babior, Gottlieb and co-workers [18,42] suggest that
cyt c is inactivated during Fas-activated apoptosis in
Jurkat cells. By measuring substrate-stimulated res-
piration rate and using absorption spectroscopy to
measure the cytochrome contents, they showed that
the measured cyt c in both the mitochondrial and
post-mitochondrial fractions were not signi¢cantly
changed during apoptosis, but the electron transfer
capacity of cyt c in the mitochondrial chain was lost.
The inactivation was caused by the permeabilization
of the mitochondrial outer membrane, and could be
prevented by over-expression of Bcl-2 or by the gen-
eral caspase inhibitor z-VAD. Because of the inhib-
ition by z-VAD, it appears likely that this inactiva-
tion of cyt c occurred as a consequence of the
receptor-mediated activation of caspase-8 or casp-
ase-1 [43]. While it is possible that their spectral
measurements did not have su⁄cient sensitivity to
measure a release of mitochondrial cyt c in cultured
cells, it should also be pointed out that the Western
blot analyses by other investigators do not show
whether cyt c remains redox active. Thus, it appears
possible that the redox activity of cyt c is lost in
concert with its release, and that inhibition of the
redox activity of cyt c has an undetermined function
during apoptosis.
3. Mechanism of cytochrome c-dependent activation
of caspase-3
The mechanism of cyt c-dependent activation of
caspase-3 has been recently elucidated by Wang
and co-workers [44,45]. They puri¢ed Apaf-1 (apop-
totic protease activating factor-1) [44] and found it to
be the ¢rst identi¢ed mammalian homologue of Ced-
4 that couples cyt c to the activation of caspase-9.
The N terminus of Apaf-1 has the CARD domain
(caspase recruitment domain [46]), which is shared by
caspases 1, 2, 3, 4, 9 and Ced-4. The C-terminal side
after the CARD domain is the Ced-4 homologue
region, which contains Walker’s A- and B-box con-
sensus sequences. The rest of the C terminus of
Apaf-1 has 12 WD-40 repeats.
Activation is thought to require two steps, binding
of ATP or dATP to Walker’s boxes, and binding of
Table 1
Release of mitochondrial cytochrome c in apoptosis
Cell type Inducing agents Reference
HL 60 Staurosporine [36,39]
Etoposide
Ara-C
Paclitaxel
CEM Staurosporine [37]
Etoposide
Actinomycin D
Hydrogen peroxide
UVB
U-937 Ionizing radiation [38]
Cisplatinum
Cerebellar granule neurons
(CGN)
MPP [40]
Jurkat Anti-Fas [41]
Staurosporine
FL 5.12 IL-3 withdrawal [41]
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cyt c to the WD repeats. These interactions allow a
conformational change that exposes the CARD do-
main, where caspase-9 (Apaf-3) can bind and be ac-
tivated (Fig. 1). Since Apaf-1 does not have caspase
activity, caspase-9 is possibly cleaved through auto-
catalysis. Active caspase-9 cleaves and activates casp-
ase-3 in a cascade that subsequently cleaves casp-
ase-6, DFF (DNA fragmentation factor) [47],
PARP (poly(ADP-ribose)polymerase) and other sub-
strates, leading to the nuclear lamin cleavage, DNA
fragmentation, and other characteristic changes of
apoptosis [48]. Thus, the release of cyt c from the
mitochondria provides a key signal that initiates
the irreversible death sequence and brings the af-
fected cells to the no-return point.
While cyt c release is a proximal signal in the acti-
vation of caspase-3 by this sequence, it has also be-
come apparent that cyt c release is distal to caspase
activation in Fas-activated apoptosis. With this
mechanism of activation of apoptosis, mitochondrial
signaling seems to be unnecessary, but may nonethe-
less contribute to apoptosis as an ampli¢cation
mechanism. The death e¡ector domain (DED) [49]
of the Fas receptor associated protein FADD/
MORT1 [50,51] has structural homology to the
CARD domain and the death domain (DD) of Fas
receptor [46]. DED is shared by FADD/MORT1,
caspase-8 and TRADD (TNF receptor associated
protein) [52]. Like CARD, DED can be used by
FADD to recruit and activate caspase-8 [53,54], in
a process that occurs within minutes after receptor
oligomerization. The activated caspase-8 cleaves and
activates caspase-1, and the subsequent apoptotic
cascade.
Mitochondrial cyt c loss occurs as a consequence
of this upstream caspase activation, and general
caspase inhibitors such as z-VAD block cyt c loss
[15,18]. Thus, in contrast to the system described
by Wang and colleagues, mitochondria apparently
have a distal role in Fas-activated apoptosis. Simi-
larly, with TNF receptor mediated apoptosis, where
either TRADD recruits FADD/caspase-8 complex by
interaction of the DED domains or RAIDD recruits
caspase directly via their CARD domains [52,55,56],
mitochondria appear to have a downstream signaling
role. Discrimination between these pathways and
those dependent upon cyt c release provides an im-
portant foundation for the future classi¢cation of
apoptotic signaling pathways.
4. Gatekeeper function of Bcl-2 family proteins
Bcl-2 was originally recognized as an inhibitor of
apoptosis and found to be homologous to Ced-9, the
antiapoptotic protein of C. elegans. [57]. More than
ten members of the Bcl-2 family have been identi¢ed
and some of these have pro-apoptotic instead of anti-
apoptotic activity [58]. Despite intense investigations,
the mechanism of action of the Bcl-2 family proteins
in apoptosis has remained elusive, and this has re-
cently been further confused by the recognition of
functions of these proteins that are apparently not
related to apoptosis. These other functions include
a role in the regeneration of neurons [59] and tran-
scriptional regulation through the interaction with
NF-AT and calcineurin [60]. Thus, even though
Fig. 1. Activation cascade initiated by mitochondrial cyto-
chrome c release. Release of mitochondrial cytochrome c
(mtCyt c) from the intermembrane space into the cytoplasm
(cCyt c) allows interaction with Apaf-1 which, in the presence
of micromolar concentration of dATP or millimolar concentra-
tion of ATP, results in proteolytic activation of procaspase-9.
Active caspase-9 activates procaspase-3 by proteolytic cleavage.
Active caspase-3 subsequently cleaves a variety of substrates re-
sulting in characteristic morphologic changes in the nucleus,
DNA fragmentation, and appearance of the phagocytic marker
phosphatidylserine on the cell surface. Multiple signaling events
may activate cyt c release, but these have not yet been clearly
de¢ned. Bcl-2 functions in regulating cyt c release, but probably
has additional functions. Proximal aspects of the mitochondrial
activation pathway are distinct from those of the Fas-activation
pathway but the two pathways converge at distal steps with ac-
tivation of caspase-3.
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Bcl-2 family proteins are mammalian homologues of
Ced-9, their roles in mammalian cell function may be
quite di¡erent from that of Ced-9 in C. elegans.
The observation that over-expression of Bcl-2 and
Bcl-XL prevented the release of cyt c into the cytosol
provided an important insight into the possible anti-
apoptotic mechanisms [36^39,41]. Cyt c is on the
outside of the inner mitochondrial membrane while
Bcl-2 is associated with the outer membrane, extend-
ing to the inner surface; how they interact is not
clear. Bcl-2 or Bcl-XL over-expression protects
against apoptosis in b0 cells which do not have func-
tional mitochondria [25^27] and also in cells micro-
injected with cyt c [61,62]. These observations, plus
the recognition that Bcl-2 has functions unrelated to
apoptosis, suggest a range of possible mechanisms of
action for Bcl-2 family members (Fig. 2). These in-
clude functions in channel formation and ion move-
ment, action as a chaperone or molecular gatekeeper
that controls movement of proteins such as cyt c
across membranes, binding to apoptosis proteins as
an adaptor or docking element and as a membrane
stabilizing agent that preserves integrity of mem-
branes.
The X-ray crystallographic structure suggested a
pore-forming capacity of Bcl-2 family proteins [63].
The arranged two central hydrophobic K-helices sur-
rounded by ¢ve amphipathic K-helices structure of
Bcl-XL resembles that of bacteria diphtheria toxin
[63], and provides a theoretical structural base for
membrane insertion and pore forming function. In
synthetic lipid membranes, pro-apoptotic members,
such as Bax, can form anion selective channels, while
anti-apoptotic one, Bcl-2 and Bcl-XL, form cation
selective channels [64^67]. Because the whole length
proteins are highly insoluble, all these studies used C-
terminal truncated proteins. The binding and inser-
tion of truncated proteins, especially anti-apoptotic
ones, are pH dependent. The transmembrane ion
£ow could be increased by acidifying the solution
to pH 4.0, and at pH 6.0, the current through Bcl-
XL and Bcl-2 was not detectable. Interestingly,
although both Bcl-2 and Bax form channels in syn-
thetic lipid membranes, only Bax could lyse the neu-
rons or erythrocytes when added extracellularly. One
explanation could be that channels formed by the
anti-apoptotic ones remain closed while ones formed
by Bax are ‘constitutively active’. By heterodimeriza-
tion on the mitochondrial outer membrane, these
proteins can either promote or inhibit the cyt c re-
lease, depending on their levels of expression, and
perhaps more importantly, the ratio between them.
However, over-expression of Bcl-XL mutants that do
not bind with Bax can still inhibit apoptosis [68] or
Bax-induced cell death in budding yeast [69]. Over-
expression of Bcl-2 inhibited apoptosis induced by
direct injection of cyt c [61]. Thus, even if the Bcl-2
family members do have a channel-forming charac-
ter, it is di⁄cult to envisage how these channels func-
tion to promote or inhibit apoptosis. A further
downstream e¡ect after the mitochondria is likely
to be involved.
The conformational £exibility of apocytochrome c
that allows it to spontaneously insert and move
through the mitochondrial outer membrane is lost
upon insertion of the heme [28,29]. Thus, an alter-
native function for Bcl-2 family members related to
Fig. 2. Functions of Bcl-2 family proteins. Bcl-2 was originally
identi¢ed as an anti-apoptotic protein but is now recognized to
be a member of a larger family of proteins with pro-apoptotic
as well as anti-apoptotic members. The emerging view is that
the opposing functions are regulated transcriptionally as well as
by phosphorylation/dephosphorylation, proteolysis and protein-
protein interactions. Suggested functions include: A, as a chan-
nel; B, as a chaperone or gatekeeper that controls chaperone
function; C, as an adaptor or docking protein; D, as a protein
that regulates membrane stability. As a channel (A) pro-apop-
totic members have an anionic speci¢city and anti-apoptotic
members have a cationic speci¢city. As a chaperone or gate-
keeper of chaperone activity (B), pro-apoptotic members pro-
mote movement in a death-signaling direction (e.g., cyt c re-
lease, loss of protease compartmentation) while anti-apoptotic
members block such movement. As an adaptor or docking pro-
tein (C), pro-apoptotic members could facilitate activation of
apoptosis by bringing key elements together while anti-apop-
totic members could serve to block such interactions. As a pro-
tein that stabilizes membranes (D), the activity can be viewed
in analogy to the components that function in fragmentation of
the nuclear envelope during mitosis. Pro-apoptotic members
will destabilize the membrane, promoting release of intermem-
brane components (i.e., cyt c from mitochondria) or fragmenta-
tion into apoptotic bodies (i.e., nuclear and plasma membrane
blebbing). Anti-apoptotic members will function as membrane
stabilizing or vesicle fusion proteins.
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channel-forming ability could be to function as a
chaperone molecule, or a molecular gatekeeper that
works in concert with a chaperone system, to control
movement of macromolecules from one compart-
ment to another. The research of Samali and Cotter
[70] suggests involvement of chaperones in control of
apoptosis because increased expression of heat shock
proteins inhibit apoptosis. Moreover, BAG-1, a mul-
tifunctional protein that binds Bcl-2, regulates chap-
erone activity of Hsc70 and also inhibits apoptosis
[71]. Such a gatekeeper activity of Bcl-2 family mem-
bers would place these proteins functionally at a po-
sition where they could control processes such as
release of mitochondrial cyt c to activate apoptosis
and also have other functions such as in the nuclear
uptake of transcription factors or the movement of
proteins across the endoplasmic reticulum. Regula-
tion of Bcl-2 via phosphorylation, proteolysis or in-
teraction with other family members could transform
it from an inhibitor to a mediator of transmembranal
protein tra⁄cking. Such an activity could also ex-
plain the rather enigmatic localization of Bcl-2 in
di¡erent membrane compartments and the ability
of Bax and other family members to induce cell
death.
On the other hand, Bcl-2 family members directly
bind with apoptosis elements in vitro [38], suggesting
that Bcl-2 family members could have direct protein
regulatory activity, perhaps being an adaptor or
docking protein [72]. This was determined with co-
immunoprecipitation, Far Western blot and ELISA.
Bcl-Xs did not bind cyt c, and excess Bcl-Xs could
compete o¡ the binding. Although this does not ex-
clude a channel or gatekeeper mechanism, it provides
an alternative mechanism to inhibit the cyt c-depend-
ent caspase activation. Moreover, it implies a further
downstream e¡ect of Bcl-2 family proteins after the
cyt c is released or when cyt c is microinjected into
cells [61].
More recently, Bcl-XL has been shown to protect
against mitochondrial swelling and outer membrane
breakdown [41]. Anti-Fas, staurosporine and IL-3
withdrawal all induced an early hyperpolarization
and swelling of mitochondria before cyt c was re-
leased. Both the volume and potential change con-
tributed to the increased mitochondrial uptake of
potential-dependent £uorescent dye during early
apoptosis, a phenomenon which had been reported
before [73]. Inconsistent with other studies of mito-
chondria during apoptosis, high resolution electron
microscopy showed a disruption of the mitochondria
outer membrane, which the authors concluded was
due to the initial swelling of mitochondria during
early stages of apoptosis. Thus, they interpreted
that cyt c was released once the outer membrane
was damaged. Further support came from the fact
that over-expression of Bcl-XL prevented oligomycin
induced hyperpolarization of mitochondria and sub-
sequent mitochondrial swelling and cytochrome c re-
lease. Similar results were obtained with antimycin
A, which also caused mitochondrial swelling and cy-
tochrome c release that were blocked by over-expres-
sion of Bcl-XL. Thus, an alternate function of Bcl-2
family members, as illustrated by this Bcl-XL study,
is that they could act to protect the integrity of the
mitochondrial outer membrane regardless of the na-
ture of initial stimulus.
While such a possibility may seem somewhat far-
fetched, it should be noted that Bcl-2 over-expression
has been previously reported to protect against ne-
crotic cell death [74], suggesting that membranal sta-
bilization may be an important function of this pro-
tein. As membrane budding and fusion are ongoing,
controlled processes in cells and the nuclear envelope
undergoes a controlled fragmentation and reforma-
tion during mitosis, a role for Bcl-2 family members
in membrane stability is rather appealing because it
suggests functions of Bcl-2 family members that
could be important in normal cell growth and di¡er-
entiation, as well as apoptosis. Pro-apoptotic mem-
bers could facilitate membrane blebbing and frag-
mentation while anti-apoptotic members could
stabilize large continuous membrane domains.
5. Is caspase activation synonymous with apoptosis?
In earlier studies of apoptosis, DNA fragmenta-
tion was taken as a ‘biochemical hallmark of apop-
tosis’ [75]. Subsequent studies revealed that DNA
fragmentation was not a ubiquitous characteristic
of cells with morphologic features of apoptosis [76]
and only recently has an appropriate endonuclease
system been identi¢ed [77]. Thus, it is appropriate
to raise the question whether sequential activation
of caspases provides a useful biochemical de¢nition
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of apoptosis, or whether the de¢nition of apoptosis
should be maintained strictly as a morphological
term.
The question needs to be addressed in three ways:
whether the spectrum of caspases and morphologic
changes associated with their activation are suitably
similar to warrant inclusion within a single concep-
tual framework, whether some of the caspases have
functions other than apoptosis, and whether mor-
phologic processes currently identi¢ed as apoptosis
can occur via activation processes not involving
caspases. Considerable information is available on
the caspases and distinction between activation
sequences, such as between Fas-activated and cyt
c-mediated pathways are already apparent. Thus, it
appears likely that further classi¢cation of apoptosis
will be possible based upon morphologic and bio-
chemical characteristics, and, within this framework,
that mitochondria-dependent mechanisms will con-
stitute at least one of these classes.
However, simple de¢nition of apoptosis in terms
of caspase-dependent signaling will probably be elu-
sive even though these important enzymes may be
central to apoptosis in most systems. Caspase-1, in-
terleukin-1L converting enzyme (ICE), was known
before the family of ‘death proteases’ was recognized
[78]. Non-apoptotic functions of caspases are likely
to exist and are being discovered. For instance, casp-
ase-3 has recently been identi¢ed to be required for
the processing and activation of pro-interleukin-16
[79]. Pro-interleukin-16 has no signi¢cant sequence
similarity to pro-interleukin-1L, and the spectra of
biological activities of these interleukins are di¡erent
[79]. Thus, the results indicate that even caspase-3,
the protease most closely homologous with the C.
elegans death protease Ced-3 and playing the critical
role in cyt c-dependent apoptosis, may have non-
apoptotic functions.
Further investigation is likely to reveal activation
systems for controlled cell deletion that are signaled
by caspase-independent mechanisms. For instance,
activation of the respiratory burst in neutrophils
with phorbol ester is followed by cell death that
has neither apoptotic nor necrotic morphology [80],
and so do the L929 ¢broblast cells treated with 0.1
and 0.5 mM H2O2 for up to 2 days [81]. Whether
such cell death is dependent upon caspases is not yet
apparent, but such cases will require that either
‘apoptosis’ be rede¢ned in terms of the biochemistry
or that more critical morphologic criteria be estab-
lished. In either case, additional e¡orts are needed to
allow discrimination of caspase-dependent and casp-
ase-independent cell death and ultimately determine
whether caspase activation provides a useful bio-
chemical de¢nition that is synonymous with the mor-
phologic de¢nition of apoptosis.
6. Redox signaling of apoptosis
An unresolved issue of mitochondria-mediated
apoptosis lies in the role of redox signaling. Consid-
erable circumstantial evidence suggests that mito-
chondrial signaling of apoptosis may not be limited
to the role of cyt c in activation of caspase-3 and that
reactive oxygen species (ROS) may provide an alter-
nate signaling pathway. Several studies show that
Fas activation and TNFK treatment of cells results
in stimulated mitochondrial generation of ROS [82].
Moreover, a variety of oxidants activate apoptosis
[83], induction of apoptosis is commonly associated
with an oxidation of the cellular glutathione pool
[84], and thiols such as N-acetylcysteine commonly
inhibit apoptosis [85]. Because mitochondria have a
central role in cellular redox regulation, these sepa-
rate observations indicate that mitochondria may
provide a redox signal to activate the key processes
of apoptosis in parallel to the cyt c-dependent acti-
vation of caspase-3.
It is well known that the mitochondrial permeabil-
ity transition (MPT) is activated by oxidants [86],
and the data by Kroemer and colleagues show that
the MPT is associated with apoptosis in many sys-
tems [87]. Thus, the alteration in mitochondrial elec-
tron transport and oxidant production associated
with loss of cyt c could activate the MPT and pro-
vide an alternate apoptosis signaling mechanism that
is functionally redundant to the caspase-3 activation
and serves to guarantee cell death.
MPT is a well studied phenomenon [86] wherein
the normally highly impermeable mitochondrial in-
ner membrane abruptly becomes permeable to mol-
ecules of less than 2 kDa. The MPT occurs as a
consequence of the reversible opening of megachan-
nels at the contact regions on the inner and outer
membranes of mitochondria. Upon opening of the
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permeability pore, rapid ion movement causes exten-
sive mitochondrial swelling and loss of the mitochon-
drial membrane potential. Kroemer and his co-work-
ers have postulated that the MPT is a common
apoptotic ‘e¡ector’. A protein factor of around 50
kDa, AIF, is suspected to be released from mito-
chondria following the MPT and function as a cen-
tral executioner of apoptosis [2]. A review on this
topic is included in the present issue of this series
[88].
Although isolated mitochondria can release cyt c
under in vitro conditions when MPT is triggered [89],
in the context of an intact cell, cyt c can be released
when most of the mitochondria retain a normal or
near-normal membrane potential. This has been re-
ported by separate studies with HL60 cells, Jurkat
cells, PC-12 cells, FL5.12 pro-B, using di¡erent
apoptosis inducing agents [36,37,41]. Although it re-
mains possible that a small subfraction of mitochon-
dria can undergo the MPT, release cyt c or AIF and
induce apoptosis, it is clear that most of the mito-
chondria do not undergo the permeability transition
early enough to explain cyt c release under these
conditions. Furthermore, microinjection of cyt c
into di¡erent cell types induces apoptosis, apparently
without activation of the MPT [61,62]. Thus
although MPT is su⁄cient to release cyt c, it is not
required for its release.
The study of Krippner et al. [15] showed that mi-
tochondrial respiration is dramatically inhibited as a
consequence of loss of cyt c activity in Fas-activated
Jurkat cells. We have found that induction of apop-
tosis in HL60 cells with TNFK or staurosporine sim-
ilarly resulted in inhibited mitochondrial respiration
[90]. Inhibition of normal electron transport through
the mitochondrial electron transport chain with cya-
nide or antimycin A results in diversion of electron
£ow from the middle portion of the chain directly to
O2 to produce superoxide [91]. Similarly, loss of cyt c
from mitochondria, as occurs during apoptosis, re-
sults in stimulated superoxide production [90]. Pre-
vention of cyt c release from mitochondria by over-
expression of Bcl-2 also prevented the increase in
superoxide production. Thus, enhanced mitochon-
drial production of reactive oxygen species appears
to be a consequence of cyt c release, and the antiox-
idant function of Bcl-2 is due to its e¡ect on cyt c
release. This, together with the export of reduced
glutathione from apoptotic cells [92], can lead to
dramatic oxidation of intracellular thiol pools. Since
MPT pore has critical thiol groups, the redox change
subsequent to the cyt c release can trigger the MPT.
MPT can also be activated by caspases such as
occurs in Fas-mediated apoptosis, where it is blocked
by the general caspase inhibitor, z-VAD [93]. Taken
together, a picture emerges that MPT and cyt c re-
lease are two separate but interacting events. MPT
can release cyt c, and vice versa. The ¢nal execution
phase of apoptosis does not appear to need the acti-
vation of both pathways. Rather, this apparent re-
dundancy may provide a fail-safe system that insures
cell death even when one of the pathways does not
function properly. Once activated, either pathway
can execute a death program and together they pro-
vide a positive feedforward mechanism that protects
against failure of apoptosis.
7. Mitochondria-mediated apoptosis in disease
The importance of apoptosis in human disease and
its treatment has been widely recognized and fre-
quently reviewed [94]. In cardiac ischemia-reperfu-
sion, mitochondria are central to the ROS generation
and calcium-associated damage [95]. In numerous
types of chemical-induced liver or renal injury, toxic
e¡ects are thought to occur via e¡ects on the mito-
chondria [96]. Oxidative damage to mitochondria
also appears to have a central role in neurodegener-
ative diseases [97]. Defective apoptosis contributes to
malignancy, and subnormal and aberrant mitochon-
dria may contribute to the resistance of tumor cells
to apoptosis [98]. Thus, the recognition of mitochon-
drial signaling provides an important opportunity for
improved understanding of the role of apoptosis in
these disease processes.
While review of all these diverse pathologic proc-
esses is beyond the scope of this brief review, two
general aspects are worthy of consideration, namely
that mitochondrial signaling of apoptosis evolved to
protect against the age-related oxidative damage to
mitochondria and that model systems used to study
apoptosis may be largely inadequate to investigate
age-dependent diseases of primary interest.
The mitochondrial genome is more sensitive to
mutation than the nuclear genome, and mtDNA
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damage, including both base damage and large dele-
tions, has been found to increase with age in all post-
mitotic tissues studied so far [99,100]. Mitochondrial
DNA is not covered by histones. It is localized near a
major intracellular source of ROS and, compared to
the nuclear DNA, has a high transcription rate. The
DNA repair system inside the mitochondria is not
e⁄cient. After the same level of oxidative damage,
mtDNA damage remains much longer than that of
nuclear DNA [101]. Thus, as age increases, mtDNA
damage increases and is possibly associated with de-
creased mitochondrial functions and increased gener-
ation of ROS. Apoptosis could be induced by either
a release of cyt c, by ROS signaling or by the MPT-
induced release of AIF. This would, on the one hand,
protect against oxidative mutations in the nuclear
genome and therefore prevent malignant transforma-
tion. On the other hand, it would also cause the loss
of functional cells and potentially could contribute to
degenerative processes. The former may be particu-
larly important in epithelial cells exposed commonly
to oxidants and other toxic chemical species while
the latter would be particularly important for tissues
such as the central nervous system and the retina.
Unfortunately, it is not apparent that the currently
available models for study of apoptosis are suitable
for providing a clear understanding of the role of
apoptosis in these relevant disease models. Apoptosis
is often studied with hematopoietic cells that nor-
mally have a very short half life and also have spe-
cialized systems for apoptosis related to immune
functions. This problem is compounded by the fact
that most are derived from malignancies that have
aberrant apoptotic systems. A further problem is
that conditions are usually used which provide a sub-
stantial rate of apoptosis. In contrast, a very low
frequency of cells is a¡ected in most relevant age-
related disease processes. For instance, a change in
frequency of apoptosis from 0.01% per day to 0.02%
per day may mean that an individual develops mac-
ular degeneration at age 60 instead of age 90 [102].
Such a low frequency of cell death will be hard to
discriminate from the spontaneous cell death under
in vitro cultured conditions. At present, we do not
know whether acute toxicity model systems in which
more than 50% of the cells undergo apoptosis in 4^
12 h are relevant to apoptosis as it occurs during
aging.
8. Conclusions
While there remain considerable questions con-
cerning the role of mitochondria-induced apoptosis
in human disease, recent advances in understanding
mechanisms whereby mitochondria can activate
apoptosis provide a substantial improvement in
knowledge of this important process. It is now clear
that a central and common pathway for signaling
apoptosis involves release of cyt c from mitochondria
and subsequent activation of the death protease,
caspase-3. This process is regulated in an unknown
way by members of the Bcl-2 family proteins. A mi-
tochondrially derived redox signal is simultaneously
generated as a consequence of mitochondrial cyt c
release. This, together with the MPT, may function
as an alternate ‘fail-safe’ signaling pathway for apop-
tosis or function in activation of speci¢c processes of
the execution program. However, non-mitochondrial
signaling pathways for activation of caspases and
induction of apoptosis are known and therefore ad-
ditional studies are needed to provide a suitable de-
lineation of the role of mitochondria-mediated apop-
tosis in the broader spectrum of apoptotic signaling
mechanisms.
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